{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:41:35Z","timestamp":1786549295664,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) has expanded donor availability for acute leukemia, yet the clinical relevance of emerging immunogenetic markers remains uncertain. This study investigated whether donor\u2013recipient human leukocyte antigen (HLA)-B leader matching influences transplantation outcomes in adults with acute leukemia undergoing haplo-HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective analytical cohort included consecutive adults (18\u201365\u00a0years) with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) who underwent their first haplo-HSCT at one of the most prominent referral hospitals between January 2008 and December 2022. HLA-B leader status was determined by exon 1 sequencing and classified as matched or mismatched between donor and recipient. Outcomes included overall survival (OS), disease-free survival, relapse incidence (RI), non-relapse mortality (NRM), engraftment, acute and chronic graft-versus-host disease (GVHD), and GVHD-free\/relapse-free survival (GRFS). Kaplan\u2013Meier methods, Cox regression, and competing-risk models were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 140 patients were analyzed (AML 67.9% and ALL 32.1%); 106 (75.7%) were HLA-B leader matched and 34 (24.3%) mismatched, with a median follow-up of 68\u00a0months among survivors. HLA-B leader mismatching was not associated with OS [multivariable hazard ratio (HR)\u00a0=\u00a01.02, 95% confidence interval (CI): 0.65\u20131.60;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.937] or with NRM (HR 1.28;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.34), and rates of acute GVHD (42.5% vs. 50.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.441) and chronic GVHD (25.5% vs. 29.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.65) were comparable between groups. Relapse was numerically lower in the mismatched group (11.8% vs. 24.5%; HR\u00a0=\u00a00.49, 95% CI: 0.17\u20131.41;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.184). In multivariable analysis, age 25\u201340\u00a0years (HR\u00a0=\u00a01.67, 95% CI: 1.04\u20132.68;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.034) and transplantation in CR2 or beyond (HR\u00a0=\u00a01.52, 95% CI: 1.01\u20132.84;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.045) independently predicted inferior OS; acute GVHD was associated with reduced relapse risk (HR\u00a0=\u00a00.37, 95% CI: 0.16\u20130.86;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.021). GRFS did not differ significantly by leader status (HR\u00a0=\u00a00.85;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.47).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In adults with acute leukemia undergoing PTCy-based haplo-HSCT, HLA-B leader matching was not associated with survival or GVHD. However, the observed trend toward lower relapse with leader mismatching, together with the protective association between acute GVHD and relapse, suggests a potential graft-versus-leukemia signal that warrants validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005159","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:10Z","timestamp":1782990010000},"page":"4812-4817","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of HLA-B leader matching on clinical outcomes of haploidentical hematopoietic stem cell transplantation in adult patients with acute leukemia, a retrospective cohort study"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7385-3441","authenticated-orcid":false,"given":"Nafeh","family":"Noorbakhsh","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-1347","authenticated-orcid":false,"given":"Tahereh","family":"Rostami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Rad","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kasaeian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Digestive Diseases Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Medicine, Research Center for Chronic Inflammatory Diseases, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Medicine, Clinical Research Development Unit, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Ostadali","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"R1-20260812","first-page":"17\u201348","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20260812","doi-asserted-by":"crossref","first-page":"24089","DOI":"10.1038\/s41598-025-10061-7","article-title":"Advancing the pathway to allogeneic hematopoietic stem cell transplantation through a physician\u2013nurse coordinator system in patients with acute leukemia","volume":"15","author":"Auepisit","year":"2025","journal-title":"Sci Rep"},{"key":"R3-20260812","doi-asserted-by":"crossref","first-page":"1907\u201314","DOI":"10.1007\/s00277-023-05226-1","article-title":"Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience","volume":"102","author":"Duda","year":"2023","journal-title":"Ann Hematol"},{"key":"R4-20260812","doi-asserted-by":"crossref","first-page":"1328858","DOI":"10.3389\/fimmu.2024.1328858","article-title":"The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy","volume":"15","author":"Maurer","year":"2024","journal-title":"Front Immunol"},{"key":"R5-20260812","doi-asserted-by":"crossref","first-page":"207\u201314","DOI":"10.1038\/sj.bmt.1705963","article-title":"Searching for alternative hematopoietic stem cell donors for pediatric patients","volume":"41","author":"Rocha","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R6-20260812","doi-asserted-by":"crossref","first-page":"183\u201389","DOI":"10.1053\/j.seminhematol.2018.09.002","article-title":"Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: mechanisms and results","volume":"56","author":"Elmariah","year":"2019","journal-title":"Semin Hematol"},{"key":"R7-20260812","doi-asserted-by":"crossref","first-page":"63\u201370","DOI":"10.1016\/j.blre.2014.09.009","article-title":"\u201cNo donor\u201d? Consider a haploidentical transplant","volume":"29","author":"Ciurea","year":"2015","journal-title":"Blood Rev"},{"key":"R8-20260812","doi-asserted-by":"crossref","first-page":"2772\u201381","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Malki","year":"2025","journal-title":"J Clin Oncol"},{"key":"R9-20260812","doi-asserted-by":"crossref","first-page":"44\u201351","DOI":"10.1111\/tan.15022","article-title":"HLA-B leader genotypes in a clinical population","volume":"102","author":"Balgansuren","year":"2023","journal-title":"Hla"},{"key":"R10-20260812","doi-asserted-by":"crossref","first-page":"1986943","DOI":"10.1080\/2162402X.2021.1986943","article-title":"CD8+ T lymphocytes are sensitive to NKG2A\/HLA-E licensing interaction: role in the survival of cancer patients","volume":"10","author":"Gimeno","year":"2021","journal-title":"OncoImmunology"},{"key":"R11-20260812","doi-asserted-by":"crossref","first-page":"2\u201312","DOI":"10.5045\/br.2023.2022192","article-title":"Effects of immune system cells in GvHD and corresponding therapeutic strategies","volume":"58","author":"Tavaf","year":"2023","journal-title":"Blood Res"},{"key":"R12-20260812","first-page":"362\u201369","article-title":"HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation","volume":"136","author":"Petersdorf","year":"2020","journal-title":"Blood"},{"key":"R13-20260812","first-page":"100081","article-title":"Revised Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) Guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R14-20260812","doi-asserted-by":"crossref","first-page":"110\u201318","DOI":"10.1097\/MS9.0000000000004285","article-title":"Salvage therapy with etoposide and mitoxantrone in patients with refractory acute myeloid leukemia: a retrospective cohort study","volume":"88","author":"Mirzania","year":"2026","journal-title":"Ann Med Surg"},{"key":"R15-20260812","doi-asserted-by":"crossref","first-page":"2292\u2013302","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"R16-20260812","doi-asserted-by":"crossref","first-page":"11\u201326","DOI":"10.1007\/s00428-022-03448-8","article-title":"International Consensus Classification of acute lymphoblastic leukemia\/lymphoma","volume":"482","author":"Duffield","year":"2023","journal-title":"Virchows Arch"},{"key":"R17-20260812","first-page":"270\u201380","article-title":"Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation","volume":"6","author":"Sajulga","year":"2022","journal-title":"Blood Adv"},{"key":"R18-20260812","doi-asserted-by":"crossref","first-page":"1452\u201368","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"key":"R19-20260812","doi-asserted-by":"crossref","first-page":"1723\u201327","DOI":"10.1038\/s41409-021-01231-y","article-title":"HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation","volume":"56","author":"Reusing","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R20-20260812","doi-asserted-by":"crossref","first-page":"189\u201398","DOI":"10.1016\/j.jtct.2022.11.027","article-title":"HLA factors versus Non-HLA factors for haploidentical donor selection","volume":"29","author":"Mehta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R21-20260812","doi-asserted-by":"crossref","first-page":"102005","DOI":"10.1016\/j.jcyt.2025.102005","article-title":"Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies","volume":"28","author":"Yu","year":"2026","journal-title":"Cytotherapy"},{"key":"R22-20260812","doi-asserted-by":"crossref","first-page":"100048","DOI":"10.1016\/j.bglo.2025.100048","article-title":"HLA-B leader mismatch predicts increased GVHD risk in haploidentical transplantation: insights from a Latin American cohort","volume":"2","author":"Sarmiento","year":"2025","journal-title":"Blood Glob Hematol"},{"key":"R23-20260812","doi-asserted-by":"crossref","first-page":"581\u201386","DOI":"10.1182\/hematology.2023000507","article-title":"Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment","volume":"2023","author":"Janardan","year":"2023","journal-title":"Hematology"},{"key":"R24-20260812","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/lymphatics3030019","article-title":"Biological age, aging clocks, and the interplay with lymphoid neoplasms: mechanisms and clinical frontiers","volume":"3","author":"Wu","year":"2025","journal-title":"Lymphatics"},{"key":"R25-20260812","first-page":"e92549","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia: a systematic review","volume":"17","author":"Mohamed Ahmed","year":"2025","journal-title":"Cureus"},{"key":"R26-20260812","doi-asserted-by":"crossref","first-page":"314\u201323","DOI":"10.1016\/j.bbmt.2017.10.019","article-title":"Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia: a national population-based cohort study","volume":"24","author":"\u00d8stg\u00e5rd","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-20260812","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3324\/haematol.2020.264424","article-title":"Use of the HLA-B leader to optimize cord blood transplantation","volume":"106","author":"Petersdorf","year":"2020","journal-title":"Haematologica"},{"key":"R28-20260812","doi-asserted-by":"crossref","first-page":"1347492","DOI":"10.3389\/fimmu.2024.1347492","article-title":"Metabolic instruction of the graft-versus-leukemia immunity","volume":"15","author":"Burk","year":"2024","journal-title":"Front Immunol"},{"key":"R29-20260812","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front Oncol"},{"key":"R30-20260812","first-page":"2806\u201314","article-title":"Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation","volume":"109","author":"Coupel","year":"2006","journal-title":"Blood"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:40:57Z","timestamp":1786545657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005159","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}